scispace - formally typeset
Search or ask a question

Showing papers by "Padma V. Devarajan published in 2005"


Patent
28 Sep 2005
TL;DR: In this paper, a novel pharmaceutical composition comprising polymeric nanoparticles with one or more biologically active agents/s for mucosal and or oral administration is presented. And the compositions are formulated as powders, sprays, suspension, freeze dried powders for reconstitution, tablets, capsules, pellets, wafers, patches, films, rods, pessaries, suppositories, aerosols, bioadhesive gels, creams.
Abstract: The present invention relates to a novel pharmaceutical composition comprising polymeric nanoparticles with one or more biologically active agent/s for mucosal and or oral administration. Said polymeric nanoparticles further comprise of an agent that enhances absorption of said biologically active agent/s. The compositions are formulated as powders, sprays, suspension, freeze dried powders for reconstitution, tablets, capsules, pellets, wafers, patches, films, rods, pessaries, suppositories, aerosols, bioadhesive gels, creams.

7 citations



01 Jan 2005
TL;DR: Application of Maxitarg is reported in the design of a targeted nanoparticulate drug delivery system (DDS) of doxorubicin with the specific objective of enhancing liver uptake and decreasing dose related cardiotoxicity of the drug.
Abstract: “MAXITARG” is a novel drug delivery approach to maximize drug accumulation in hepatocellular carcinoma cells. Maxitarg relies on a novel targeting agent (NTA) with high affinity for asialoglycoprotein receptors, which are over expressed in the liver carcinoma cells. The present study reports application of Maxitarg in the design of a targeted nanoparticulate drug delivery system (DDS) of doxorubicin with the specific objective of enhancing liver uptake and decreasing dose related cardiotoxicity of the drug. Alginic acid – sodium alginate nanoparticles (NP) loaded with doxorubicin and NTA were prepared by controlled gelation method using novel stabilizing agent Eudragit E100. Encapsulation efficiency (EE) of > 95% reflected minimum drug loss during processing. Average particle size of optimized nanoparticles (NP) ranged between 200550 nm. NP’s showed sustained in vitro drug release over a period of 60 hrs in pH 7.4 buffer at 37 0 C. Biodistribution study of NP revealed rapid and maximal uptake in the liver with significant drug accumulation up to 24 hrs, moreover low concentration of doxorubicin was evident in kidney, spleen and lung while negligible drug concentration was detected in heart up to 24 hrs. Plain doxorubicin however revealed high drug concentration in the heart at 1 hr detectable up to 24 hrs, moreover uptake by the liver was very low. Other tissues like lung, kidney, and spleen also showed presence of drug.

1 citations